Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07273279 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ADH1B and ALDH Gene Variants and Lung Cancer Risk

Study acronym: ALDH
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.
Trial Details
NCT Number NCT07273279
Lead Sponsor Kaohsiung Medical University
Conditions
(from sponsor)		 Condition/Disease, Lung Cancer (Diagnosis), Lung Adenocarcinoma
Related terms Adenocarcinoma of Lung, Disease, Lung Neoplasms
Enrollment 100,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov